Background: Statin therapy, specifically a lipophilic statin Pitavastatin (Livalo) in acute myocardial infarction (AMI) may play an important role by not only reducing LDL-cholesterol, but also by the pleiotrophic effects. We studied efficacy and safety of routine administration of Pitavastatin in AMI pts as a substudy of Korea AMI Registry (KAMIR). Methods:Study consisted of 895 consecutive AMI patients (pts; male 657, 73.4 %; age 62.1짹13.1) presented in 10 major percutaneous coronary intervention (PCI) centers from April 2007 to July 2008. Pitavastatin (Livalo) 2mg/day was routinely administered from presentation. We investigated change in lipid profiles and biochemical markers at baseline, 1, 6 and 12 months, the clinical outcomes up to 1 year and adverse effects. Result: Baseline characteristics showed diabetes in 24.6%, hyperlipidemia in 9.0% and smoking 46.6%. Among the 895 enrolled pts, STEMI was 64.6% and PCI was performed in 87.0%. Stent was deployed in 96.6% pts and success rate was 91.0%. Lipid profiles and inflammatory markers significantly improved with time. At 12 months, including one CABG pt, 12-month total major adverse cardiac event (MACE) was 43/890 pts (4.8%) without obvious myopathy or liver function deterioration cases (Table). Conclusion: Routine administration of 2mg Pitavastatin daily in pts with AMI showed excellent biochemical and clinical outcomes without significant adverse effects.